The Venture Codex

Participated · Seed · Jul 2024

3Daughters is a Mansfield, MA–based clinical development company focused on evolutionary healthcare for women. Its technology platform uses physics and geometry to deliver targeted therapy to the uterus. The company's lead product, 3D-001, is a frameless, magnetic, non-hormonal intrauterine device (IUD) designed to conform to a woman's body for long-acting contraception. 3D-001 is paired with a patented Slider™ system for insertion and retrieval that aims to eliminate insertion steps and the nuisance of strings. 3Daughters plans an IND filing in early 2025 and expects to start a first-in-human Phase 1 study following IND approval. Financially, the company closed a $4.7M Seed round and has launched a $15M Series A to fund 3D-001's Phase 1 study. 3Daughters, based in Mansfield, MA and led by CEO Mary Beth Cicero, is developing women's healthcare technologies. Its lead product, 3D-001, is a frameless, magnetic, nonhormonal intrauterine device for long-acting contraception. 3D-001 is designed to conform to a woman's body and pairs with the company's patented Slider™ insertion/retrieval system intended for easier and less painful insertion and removal. The company emphasizes addressing longstanding, neglected issues such as IUD insertion pain. 3Daughters closed over $2M in a first tranche of Seed financing to advance its development plans. It intends to use the funds to complete an IND filing and initiate a Phase 1 clinical trial this year.

Participated · Seed · Dec 2023

Myrias Optics is a provider of wafer-level metaoptics, diffractive optics, and AR waveguides built on a proprietary all-inorganic additive nanoimprinting process. Its technology delivers thermally stable, high-performance optical components with higher refractive indices, improved alignment tolerance, and lower cost than conventional semiconductor-based manufacturing. The company’s products target system designers in augmented reality headsets, high-speed AI data-center interconnects, consumer electronics, industrial equipment, and medical imaging platforms. Customers engage Myrias to overcome bottlenecks in durability, environmental stability, and scalable production economics. Proceeds from recent funding are being used to scale manufacturing capacity, expand pilot production lines, and execute active customer programs with Tier-1 supply-chain partners. Since inception, the firm has secured $6.9 million in capital, including venture funding and a National Science Foundation Direct-to-Phase II award, to accelerate commercialization of its metaoptic solutions.

Participated · Seed · Jun 2016

Weave Visual Analytics develops interactive data visualization and analysis software, building on more than 20 years of research from UMass Lowell's Institute for Visualization and Perception Research. Its flagship product, Weave 2 (recently announced as commercially supported Weave 2.1), is an HTML5-based open-source platform for interactive visualization. The company offers professional support, training, customization and consulting around the product. Weave reports more than 250,000 users worldwide for its open-source offering. The seed financing will support commercial development and the product launch of the first commercially supported version of Weave. The company plans to continue expanding the offering and intends to raise additional equity financing from institutional venture capital firms.